John A. Ambrose, MD

Pilot Study of Oral Rapamycin to Prevent Restenosis in Patients Undergoing Coronary Stent Therapy: Argentina Single-Center Study

08/01/2008

Miguel Russo , MD;

John A. Ambrose , MD;

Claudio Llaurado , BS;

Carlos Fernandez-Pereira , MD;

Alfredo E. Rodriguez , MD, PhD;

Renu Virmani , MD, PhD;

Maximo Rodriguez Alemparte , MD;

Cesar F. Vigo , MD;

Observational and randomized studies recently showed that sirolimus-coated stents were associated with a lower rate of restenosis than bare stents.1–3 Although the restenosis rate was lower, coated stents have a significantly higher cost than...

Observational and randomized...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Prospective, Randomized, Placebo-Controlled Evaluation of Esomeprazole in Coronary Artery Disease Patients. EPAC: Esomeprazole Prevention of Atypical Chest Pains

05/26/2011

John T. Coppola , MD, FACC, FSCAI;

Ravikiran Korabathina , MD;

John A. Ambrose , MD;

John Liuzzo , MD, PhD;

Sajal Das , MD;

Mary Devoe , RN;

Saurabh Agarwal , MD;

Srmiti Deshmukh , MD;

ABSTRACT: Background. Coronary artery disease (CAD) patients experience chest pain (CP) from cardiac and non-cardiac etiologies. Objective. Proton pump inhibitor (PPI) treatment of CAD patients with atypical CP would result in less CP, as...

ABSTRACT: Background. Coronary...

05/26/2011

Journal of Invasive Cardiology

Review

Sirolimus- and Taxol-eluting Stents Differ Towards Intimal Hyperplasia and Re-endothelialization

08/01/2008

John A. Ambrose , MD;

John T. Coppola , MD, FACC, FSCAI;

John Liuzzo , MD, PhD;

In-stent restenosis of coronary arteries is the major reason for the recurrence of occlusion after successful percutaneous coronary intervention (PCI) and occurs in 20–50% of patients.1 The development of in-stent restenosis depends on...

In-stent restenosis of coronary...

08/01/2008

Journal of Invasive Cardiology

Review

The Evolving Role of Glycoprotein (GP) IIb/IIIa Receptor Blockade During Percutaneous Coronary Intervention of Saphenous Vein By

08/01/2008

John A. Ambrose , MD;

John T. Coppola , MD, FACC, FSCAI;

David J. D'Agate , DO;

Snehal Patel , MD;

Percutaneous coronary intervention (PCI) has improved the treatment of coronary artery disease. However, unlike native coronary arteries, progress in the percutaneous intervention of saphenous vein bypass grafts (SVBG) has been disappointing,...

Percutaneous coronary...

08/01/2008

Journal of Invasive Cardiology

Review

The Balance Between Anti-ischemic Efficacy and Bleeding Risk of Antithrombotic Therapy in Percutaneous Coronary Intervention: A

06/03/2010

Joel A. Lardizabal , MD;

Bipin K. Joshi , MD;

John A. Ambrose , MD;

ABSTRACT: Background. The development of newer and more potent antithrombotic agents and strategies has markedly reduced cardiovascular mortality and ischemic complications in patients with acute coronary syndromes and those undergoing...

ABSTRACT: Background. The...

06/03/2010

Journal of Invasive Cardiology